Next Financial Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Next Financial Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$89K	Buy	117 +57	+95%	+$42.7K	0.01%	1218
2021 Q3	$44K	Buy	60 +11	+22%	+$8.24K	﹤0.01%	1460
2021 Q2	$32K	Sell	49 -1	-2%	-$609	﹤0.01%	1570
2021 Q1	$28K	Sell	50 -8	-14%	-$4.74K	﹤0.01%	1510
2020 Q4	$34K	Buy	58 +3	+5%	+$1.71K	﹤0.01%	1326
2020 Q3	$29K	Buy	+55	New	+$27.9K	﹤0.01%	1281
2020 Q2	–	Sell	-34	Closed	-$12K	–	738
2020 Q1	$12K	Hold	34	–	–	﹤0.01%	1455
2019 Q4	$13K	Hold	34	–	–	﹤0.01%	1665
2019 Q3	$11K	Sell	34 -20	-37%	-$6.52K	﹤0.01%	1666
2019 Q2	$17K	Buy	+54	New	+$16.2K	﹤0.01%	1512
2019 Q1	–	Sell	-54	Closed	-$13K	–	1663
2018 Q4	$13K	Buy	54 +50	+1,250%	+$13.4K	﹤0.01%	1253
2018 Q3	$1K	Buy	+4	New	+$1.24K	﹤0.01%	1373
2017 Q4	–	Sell	-4	Closed	-$1K	–	375
2017 Q3	$1K	Hold	4	–	–	﹤0.01%	1668
2017 Q2	$1K	Hold	4	–	–	﹤0.01%	1810
2017 Q1	$1K	Hold	4	–	–	﹤0.01%	1778
2016 Q4	$1K	Buy	+4	New	+$682	﹤0.01%	2256

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Next Financial Group's BIO Position: Q4 2021 in Review

Next Financial Group increased its Bio-Rad Laboratories Class A (BIO) stake by 95% in Q4 2021, buying an estimated $42.7K and bringing the position to 117 shares worth $89K. The position accounts for 0.01% of the portfolio, ranked #1218.

Next Financial Group first reported a position in BIO in Q4 2016 and has held it in 16 quarters since. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

Next Financial Group held 117 shares of Bio-Rad Laboratories Class A worth $89K as of Q4 2021.
Next Financial Group bought 57 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $42.7K.
Bio-Rad Laboratories Class A made up 0.01% of Next Financial Group's portfolio in Q4 2021, its #1218 holding.
Next Financial Group first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 16 quarters since.
533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.